文献速递骨质疏松与钙磷/甲状旁腺

双膦酸盐在特发性骨质疏松的绝经前女性中维持特立帕肽序贯地舒单抗后的骨密度

Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为开放标签延伸研究,纳入24例特发性骨质疏松的绝经前女性,在特立帕肽序贯地舒单抗治疗后7个月启用双膦酸盐(口服阿仑膦酸钠70毫克每周或静脉唑来膦酸5毫克一次)。结果显示全组骨密度和C端肽变化小且无统计学显著性,骨密度保持稳定,未发生新发椎体或非椎体骨折。

要点

  • 特立帕肽序贯地舒单抗后,双膦酸盐期间全组骨密度和C端肽变化小且无统计学显著性。
  • 选择唑来膦酸者腰椎骨密度有小幅下降、C端肽升高,阿仑膦酸钠组更稳定。
  • 未发生新发椎体(临床或椎体骨折评估筛查)或非椎体骨折。

核心结论

  • 在接受特立帕肽序贯地舒单抗治疗后的特发性骨质疏松绝经前女性中,使用双膦酸盐后骨密度保持稳定。

研究设计与样本

  • 开放标签延伸研究,纳入24例特发性骨质疏松绝经前女性(特立帕肽-地舒单抗研究参与者)。
  • 干预为末次地舒单抗后7个月给予口服阿仑膦酸钠70毫克每周或静脉唑来膦酸5毫克一次(患者选择)。

主要发现

  • 24例女性年龄43±8岁,有低创伤成人骨折(范围0-12;9例椎体骨折)和/或极低骨密度,序贯特立帕肽-地舒单抗期间骨密度大幅增加(脊柱25±9%;全髋11±6%)。
  • 双膦酸盐延伸期间,全组平均骨密度和C端肽变化在6或12个月时小且无统计学显著性。
  • 选择唑来膦酸者(n=6)与阿仑膦酸钠者(n=18)基线年龄、体重指数、骨折、骨密度或C端肽无差异;唑来膦酸组腰椎骨密度小幅下降、C端肽升高(尤其6至12个月间),阿仑膦酸钠组更稳定。
  • 骨密度和C端肽变化在地舒单抗疗程(36个月 vs <36个月)间或20例仍绝经前与4例进入绝经者间无差异。
  • 较高的特立帕肽前C端肽(可能反映基线骨转换状态)预测更多脊柱和髋部骨丢失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: We previously reported that sequential teriparatide followed by denosumab substantially increases bone mineral density (BMD) in premenopausal idiopathic osteoporosis (PremenIOP). OBJECTIVE: To determine whether administration of bisphosphonates after denosumab cessation is associated with stable BMD in PremenIOP. DESIGN: Open-label extension study. PARTICIPANTS: Twenty-four PremenIOP Teriparatide-Denosumab Study participants. INTERVENTIONS: Oral alendronate (ALN), 70 mg weekly, or intravenous zoledronic acid (ZOL), 5 mg once (patient choice), was administered 7 months (M) after final denosumab dose. OUTCOMES: BMD by dual-energy x-ray absorptiometry and serum C-telopeptide (CTX) q6M; Vertebral Fracture Assessment (VFA), and high-resolution peripheral quantitative computed tomography (HR-pQCT) q12 M. RESULTS: Twenty-four women with PremenIOP (aged 43 ± 8 years), severely affected with low trauma adult fractures (range 0-12; 9 with vertebral fractures) and/or very low BMD, had large BMD increases on sequential teriparatide-denosumab (spine: 25 ± 9%; total hip: 11 ± 6%). During the Bisphosphonate Extension, mean BMD and CTX changes in the entire group were small and not statistically significant at 6 or 12 M.Women choosing ZOL (n = 6) vs ALN (n = 18) did not differ by baseline age, body mass index, fractures, BMD, or CTX. On ZOL, there were small lumbar spine BMD declines and CTX increases, particularly between 6 M and 12 M, while greater stability was observed on ALN.Changes in BMD and CTX did not differ by duration of denosumab (36 M vs <36 M) or between 20 women who remained premenopausal and 4 who transitioned into menopause. Higher pre-teriparatide CTX, likely reflecting baseline remodeling status, predicted more spine and hip bone loss. No new vertebral (clinical or vertebral fraction assessment screening) or nonvertebral fractures occurred. CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kamanda-Kosseh M, Shiau S, Agarwal S, et al. Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2025. PMID: 38605469. doi:10.1210/clinem/dgae240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。